Abstract
Vaccination is crucial in combatting the severe acute respiratory syndrome coronavirus 2 pandemic. The rare complication of thrombocytopenia and thrombotic complications at unusual sites after ChAdOx1 nCov-19 vaccination is caused by platelet-activating antibodies directed against platelet factor 4 (PF4). We present a widely applicable whole-blood standard flow cytometric assay to identify the pathogenic antibodies associated with vaccine-induced immune-mediated thrombotic thrombocytopenia (VITT) after ChAdOx1 nCov-19 vaccination. This assay will enable rapid diagnosis by many laboratories. This trial was registered at www.clinicaltrials.gov as #NCT04370119.
© 2021 by The American Society of Hematology.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibody Specificity
-
Autoantibodies / biosynthesis
-
Autoantibodies / blood*
-
Autoantibodies / immunology
-
COVID-19 / prevention & control*
-
COVID-19 Vaccines / adverse effects*
-
COVID-19 Vaccines / immunology
-
ChAdOx1 nCoV-19
-
Flow Cytometry / methods*
-
Heparin / adverse effects
-
Heparin / immunology
-
Humans
-
Immunoenzyme Techniques
-
Immunogenicity, Vaccine
-
Immunoglobulin G / biosynthesis
-
Immunoglobulin G / blood*
-
Immunoglobulin G / immunology
-
P-Selectin / analysis
-
Platelet Activation / immunology*
-
Platelet Factor 4 / immunology*
-
Purpura, Thrombocytopenic, Idiopathic / diagnosis*
-
Purpura, Thrombocytopenic, Idiopathic / etiology
-
Purpura, Thrombocytopenic, Idiopathic / immunology
-
Receptors, IgG / immunology*
-
SARS-CoV-2*
-
Vaccination / adverse effects*
Substances
-
Autoantibodies
-
COVID-19 Vaccines
-
Fc gamma receptor IIA
-
Immunoglobulin G
-
P-Selectin
-
PF4 protein, human
-
Receptors, IgG
-
SELP protein, human
-
Platelet Factor 4
-
Heparin
-
ChAdOx1 nCoV-19
Associated data
-
ClinicalTrials.gov/NCT04370119